Welcome to our dedicated page for Shockwave Medical news (Ticker: SWAV), a resource for investors and traders seeking the latest updates and insights on Shockwave Medical stock.
Shockwave Medical, Inc. (SWAV) pioneers transformative cardiovascular therapies using its proprietary intravascular lithotripsy technology. This dedicated news hub provides investors and medical professionals with essential updates on the company’s advancements in treating calcified arterial disease.
Access consolidated, up-to-date information on SWAV’s regulatory milestones, clinical trial outcomes, and strategic initiatives. Our repository includes verified press releases covering product approvals, partnership announcements, and financial performance reports, all critical for evaluating the company’s market position.
Key updates feature developments in lithoplasty systems for coronary/peripheral arteries and the Shockwave Reducer for refractory angina. Track progress in real-world clinical adoption and research validating the safety profile of these minimally invasive solutions.
Bookmark this page to stay informed about Shockwave Medical’s innovations reshaping interventional cardiology. Regularly updated with authoritative sources, it serves as your primary resource for objective, compliance-focused reporting on SWAV’s contributions to medical technology.
Shockwave Medical announced successful results from the Disrupt CAD III study, which met primary safety and effectiveness endpoints for its Coronary IVL System. The study involved 384 patients across four countries, showing a 30-day freedom from major adverse cardiovascular events (MACE) rate of 92.2% and a procedural success rate of 92.4%. These findings highlight the device's efficacy in treating severely calcified coronary lesions, establishing a new benchmark in interventional cardiology.
Shockwave Medical (NASDAQ: SWAV) has rescheduled its CAD III Investor Webcast Event to take place on October 15, 2020, at 2:30 p.m. ET, during TCT Connect. The webcast will feature the presentation of the DISRUPT CAD III trial results by a principal investigator, a panel discussion, and a Q&A session. Interested attendees can access the live audio webcast through the Investors section on the company's website. Shockwave is dedicated to advancing the treatment of calcified cardiovascular disease using its innovative Intravascular Lithotripsy technology.
Shockwave Medical (NASDAQ: SWAV) announced that pivotal results from the DISRUPT CAD III study will be presented at TCT Connect on October 15, 2020. This study is critical as it assesses the safety and effectiveness of the Shockwave Coronary IVL System in treating severely calcified coronary arteries, enrolling 384 patients at 47 sites across multiple countries. The study's results could significantly impact treatment protocols for coronary artery disease.
Shockwave Medical, Inc. (NASDAQ: SWAV) announced its participation in the Canaccord Genuity 40th Annual Growth Conference, set for August 11-13, 2020. The company will host a live fireside chat on August 12, 2020, at 2:30 p.m. Eastern Time, which can be accessed via a webcast on their website. Shockwave Medical specializes in Intravascular Lithotripsy (IVL), a novel technique aimed at improving treatment outcomes for complex calcified cardiovascular disease through sonic pressure waves. For further details, visit their investor relations page.
Shockwave Medical (Nasdaq: SWAV) announced it will release its Q2 2020 financial results on August 11, 2020, after market close. A teleconference will follow, starting at 1:30 p.m. PT / 4:30 p.m. ET. Investors can listen live by calling (866) 795-9106 (domestic) or (470) 495-9173 (international) and using conference ID 8889064. Shockwave Medical specializes in Intravascular Lithotripsy (IVL)
Shockwave Medical (NASDAQ: SWAV) announced the appointment of Maria Sainz to its Board of Directors and Compensation Committee on July 20, 2020. Sainz brings over 25 years of experience in medical technology, having held leadership roles at Aegea Medical, Cardiokinetix, and Concentric Medical. Her expertise in commercialization and product launches is expected to bolster Shockwave’s growth as it advances its Intravascular Lithotripsy (IVL) technology aimed at treating calcified cardiovascular disease. The company is focused on establishing new standards for patient care in this area.
Shockwave Medical (NASDAQ: SWAV) announced a ruling from the USPTO regarding inter partes review cases initiated by Cardiovascular Systems, Inc. (CSI). The PTAB upheld the validity of a key claim of Shockwave's U.S. Patent No. 8,956,371 while invalidating some claims of this patent and all claims of U.S. Patent No. 8,728,091. Shockwave disagrees with the invalidity findings and intends to appeal. Despite these challenges, all claims remain enforceable until the appeals are resolved, and the company continues to develop its Intravascular Lithotripsy (IVL) technologies, benefiting over 30,000 patients.
Shockwave Medical, Inc. (SWAV) has announced pricing for its public offering of 1,700,000 shares at $45.75 each, aiming for gross proceeds of approximately $77.8 million. This offering is scheduled to close on June 19, 2020, pending customary conditions. Underwriters also hold a 30-day option to purchase an additional 255,000 shares. Morgan Stanley and BofA Securities are leading the offering, with funds intended for expanding operations and further product development in treating calcified cardiovascular disease.
Shockwave Medical (SWAV) announced a public offering of 1,700,000 shares of its common stock, with a 30-day option for underwriters to purchase an additional 255,000 shares. The offering is subject to market conditions and has no guaranteed completion date. Morgan Stanley and BofA Securities are leading the offering. The registration statement for these securities has been filed with the SEC and became effective upon filing. This offering aims to strengthen Shockwave's position in the cardiovascular treatment market, specifically using Intravascular Lithotripsy technology.
Shockwave Medical (SWAV) announced that the Centers for Medicare & Medicaid Services (CMS) issued new coding for Intravascular Lithotripsy (IVL) procedures in peripheral arteries, effective July 1 and October 1, 2020. These codes will align Medicare payment rates for IVL with other similar procedures, validating the technology as a unique treatment for calcified cardiovascular disease. CEO Doug Godshall noted this decision enables CMS to gather cost data specific to IVL, essential for future reimbursement adjustments.
FAQ
What is the current stock price of Shockwave Medical (SWAV)?
What is the market cap of Shockwave Medical (SWAV)?
